Here are Antti’s comments on the fact that Orion’s licensing partner Tenax Therapeutics’ phase 3 study did not meet its primary endpoint.
5 Likes
Here are Antti’s comments on the fact that Orion’s licensing partner Tenax Therapeutics’ phase 3 study did not meet its primary endpoint.